{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:08:10Z","timestamp":1791043690270,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["AB22035078"],"award-info":[{"award-number":["AB22035078"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project","award":["S2017077"],"award-info":[{"award-number":["S2017077"]}]},{"name":"Guangxi Nanning Qingxiu District Science and Technology Development Project","award":["2014S06"],"award-info":[{"award-number":["2014S06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Today, diabetes mellitus (DM) has become a worldwide concern. DM is a major risk factor for the development of cardiovascular diseases (CVD). Eligible patients with CVD are treated invasively by percutaneous coronary intervention (PCI) whereby a stent is implanted inside the coronary vessel with the particular lesion to allow sufficient blood flow. Newer scientific research have shown that even though associated with a lower rate of re-stenosis, first-generation drug eluting stents (DES) were associated with a higher rate of late stent thrombosis. Recently, newer stents, namely biodegradable polymer DES (BP-DES) have been developed to overcome the safety issues of earlier generation DES. In this analysis we aimed to systematically compare the long term (\u2265\u200912 months) adverse cardiovascular outcomes observed in DM versus non-DM patients who were implanted with BP-DES.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cochrane central, MEDLINE (Subset PubMed), EMBASE, Web of Science, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ClinicalTrials.gov\">http:\/\/www.ClinicalTrials.gov<\/jats:ext-link> and Google scholar were searched for relevant publications involving BP-DES in patients with DM versus non-DM and their associated adverse cardiovascular outcomes. The mean follow-up time period ranged from 12 to 120 months. Data analysis was carried out with the latest version of the RevMan software (version 5.4). Based on the Mantel-Haenszel test, risk ratios (RR) with 95% confidence intervals (CI) were calculated and used to represent the results following analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seven (7) studies with a total number of 10,246 participants were included in this analysis. Stents which were implanted during PCI were BP-DES. Participants were enrolled from the year 2006 to 2013. Our current results showed that in patients who were implanted with BP-DES, the risks of major adverse cardiac events (RR: 1.30, 95% CI: 1.18\u20131.43; P\u2009=\u20090.00001), myocardial infarction (RR: 1.48, 95% CI: 1.14\u20131.93; P\u2009=\u20090.003), all-cause mortality (RR: 1.70, 95% CI: 1.29\u20132.23; P\u2009=\u20090.0002), cardiac death (RR: 1.93, 95% CI: 1.28\u20132.93; P\u2009=\u20090.002), target vessel revascularization (RR: 1.35, 95% CI: 1.03\u20131.77; P\u2009=\u20090.03), target lesion revascularization (RR: 1.28, 95% CI: 1.07\u20131.54; P\u2009=\u20090.007) and target lesion failure (RR: 1.79, 95% CI: 1.52\u20132.12; P\u2009=\u20090.00001) were significantly higher in the DM group. Definite and probable stent thrombosis (RR: 1.80, 95% CI: 1.28\u20132.55; P\u2009=\u20090.0009) were also significantly higher in the DM group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Diabetes mellitus was an independent risk factor associated with long term adverse cardiovascular outcomes following PCI with BP-DES.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01962-w","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:02:01Z","timestamp":1693310521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term cardiovascular outcomes of biodegradable polymer drug eluting stents in patients with diabetes versus non-diabetes mellitus: a meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quannan","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiren","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"1","key":"1962_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAbdulB Khan","year":"2020","unstructured":"Khan MAbdulB, Hashim MJ, King JK, Govender RD, Mustafa H. Juma Al Kaabi. Epidemiology of type 2 diabetes - global burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107\u201311.","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"1962_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"C-X Ma","year":"2022","unstructured":"Ma C-X, Ma X-N, Guan C-H, Li Y-D. D\u00eddac Mauricio, Song-Bo Fu. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74.","journal-title":"Cardiovasc Diabetol"},{"issue":"32","key":"1962_CR3","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.2174\/1381612811319320005","volume":"19","author":"TV Fiorentino","year":"2013","unstructured":"Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19(32):5695\u2013703.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1962_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","volume":"17","author":"M Raminderjit Kaur","year":"2018","unstructured":"Raminderjit Kaur M, Kaur J, Singh. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121.","journal-title":"Cardiovasc Diabetol"},{"key":"1962_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.carrev.2022.06.254","volume":"44","author":"Tamim","year":"2022","unstructured":"Tamim, Akbari. Rasha Al-Lamee. Percutaneous coronary intervention in Multi-Vessel Disease. Cardiovasc Revasc Med. 2022;44:80\u201391.","journal-title":"Cardiovasc Revasc Med"},{"issue":"1","key":"1962_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12938-021-00883-7","volume":"20","author":"JR Stevens","year":"2021","unstructured":"Stevens JR, Zamani A, Osborne JIanA, Zamani R, Mohammad Akrami. Critical evaluation of stents in coronary angioplasty: a systematic review. Biomed Eng Online. 2021;20(1):46.","journal-title":"Biomed Eng Online"},{"issue":"1","key":"1962_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ccd.26640","volume":"88","author":"B William","year":"2016","unstructured":"William B, Hillegass. End of the bare metal stent era? Catheter Cardiovasc Interv. 2016;88(1):49\u201350.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"8","key":"1962_CR8","first-page":"CD012481","volume":"8","author":"EE Joshua Feinberg","year":"2017","unstructured":"Joshua Feinberg EE, Nielsen J, Greenhalgh J, Hounsome NJ, Sethi S, Safi C, Gluud, Janus C, Jakobsen. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database Syst Rev. 2017;8(8):CD012481.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1962_CR9","first-page":"516","volume":"37","author":"P-P Hao","year":"2010","unstructured":"Hao P-P, Chen Y-G, Wang X-L, Zhang Y. Efficacy and safety of drug-eluting stents in patients with acute ST-segment-elevation myocardial infarction: a meta-analysis of randomized controlled trials. Tex Heart Inst J. 2010;37(5):516\u201324.","journal-title":"Tex Heart Inst J"},{"issue":"11","key":"1962_CR10","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.cjca.2013.04.001","volume":"29","author":"KN Huang","year":"2013","unstructured":"Huang KN, Sonia M, Grandi KB, Filion, Mark J, Eisenberg. Late and very late stent thrombosis in patients with second-generation drug-eluting stents. Can J Cardiol. 2013;29(11):1488\u201394.","journal-title":"Can J Cardiol"},{"issue":"12","key":"1962_CR11","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2004.07.060","volume":"44","author":"R Pedro","year":"2004","unstructured":"Pedro R, Moreno V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44(12):2293\u2013300.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1962_CR12","first-page":"374","volume":"47","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhou H. Hyper-reactive platelets and type 2 diabetes. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47(3):374\u201383.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"2","key":"1962_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3904\/kjim.2011.26.2.145","volume":"26","author":"T-H Yang","year":"2011","unstructured":"Yang T-H, Kim D-I, Kim D-K, et al. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med. 2011;26(2):145\u201352.","journal-title":"Korean J Intern Med"},{"issue":"3","key":"1962_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.118.038378","volume":"139","author":"Sripal Bangalore","year":"2019","unstructured":"Sripal Bangalore. The Elusive Late Benefit of Biodegradable Polymer Drug-Eluting Stents. Circulation. 2019;139(3):334\u20136.","journal-title":"Circulation"},{"issue":"5","key":"1962_CR15","first-page":"599","volume":"58","author":"GB Danzi","year":"2010","unstructured":"Danzi GB, Chevalier B, Ostojic M, Hamilos M, Wijns W. Nobori\u2122 drug eluting stent system: clinical evidence update. Minerva Cardioangiol. 2010;58(5):599\u2013610.","journal-title":"Minerva Cardioangiol"},{"key":"1962_CR16","doi-asserted-by":"crossref","unstructured":"Yanyu Wang P, Dong L, Li X, Li H, Wang X, Yang S, Wang Z, Li X. Shang. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents for patients with coronary artery disease: an update meta-analysis. Cardiovasc Drugs Ther. 2014;28(4):379 \u2013 85.","DOI":"10.1007\/s10557-014-6528-7"},{"issue":"22","key":"1962_CR17","doi-asserted-by":"publisher","first-page":"e013607","DOI":"10.1161\/JAHA.119.013607","volume":"8","author":"F Juan","year":"2019","unstructured":"Juan F, Iglesias D, Heg M, Roffi, et al. Five-year outcomes in patients with diabetes Mellitus treated with Biodegradable Polymer Sirolimus-Eluting Stents Versus durable polymer everolimus-eluting stents. J Am Heart Assoc. 2019;8(22):e013607.","journal-title":"J Am Heart Assoc"},{"key":"1962_CR18","doi-asserted-by":"crossref","unstructured":"Lee DH, Park TK, Song YB Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents.  PLoS One. 2017 Aug 10;12(8):e0183079.","DOI":"10.1371\/journal.pone.0183079"},{"key":"1962_CR19","doi-asserted-by":"crossref","unstructured":"Lenz T, Koch T, Joner M et al. Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. J Am Heart Assoc. 2021;10(12):e020165.","DOI":"10.1161\/JAHA.120.020165"},{"issue":"7","key":"1962_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ccd.24649","volume":"81","author":"Y Li","year":"2013","unstructured":"Li Y, Han Y, Zhang L, et al. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Catheter Cardiovasc Interv. 2013;81(7):1127\u201333.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1962_CR21","first-page":"8636050","volume":"2021","author":"A Piotr Rola","year":"2021","unstructured":"Piotr Rola A, W\u0142odarczak M, Barycki, et al. Biodegradable polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: a one-year clinical outcome of two Sirolimus-Eluting Stents. J Diabetes Res. 2021;2021:8636050.","journal-title":"J Diabetes Res"},{"issue":"1","key":"1962_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12933-018-0758-0","volume":"17","author":"X-F Tang","year":"2018","unstructured":"Tang X-F, Ma Y-L, Song Y, et al. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. Cardiovasc Diabetol. 2018;17(1):114.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1962_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12933-017-0500-3","volume":"16","author":"S Marcus Wiemer","year":"2017","unstructured":"Marcus Wiemer S, Stoikovic A, Samol, et al. Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. Cardiovasc Diabetol. 2017;16(1):23.","journal-title":"Cardiovasc Diabetol"},{"key":"1962_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"PT Julian","year":"2011","unstructured":"Julian PT, Higgins DG, Altman, Peter C, G\u00f8tzsche, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"9","key":"1962_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"Andreas Stang","year":"2010","unstructured":"Andreas Stang. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"1962_CR26","first-page":"n71","volume":"372","author":"J Matthew","year":"2021","unstructured":"Matthew J, Page JE, McKenzie, Patrick M, Bossuyt, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1962_CR27","doi-asserted-by":"crossref","unstructured":"Xiang Wang X, Chen W, Sun et al. Very late stent thrombosis in drug-eluting stents New Observations and clinical implications. Cardiol Rev 2019 Nov\/Dec;27(6):279\u201385.","DOI":"10.1097\/CRD.0000000000000283"},{"issue":"1","key":"1962_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R. Kristi Skorija, Herman K Gold, Renu Virmani. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193\u2013202.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1962_CR29","first-page":"81","volume":"6","author":"Y Chirag Bavishi","year":"2020","unstructured":"Chirag Bavishi Y, Chugh T, Kimura, et al. Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials. Eur Heart J Qual Care Clin Outcomes. 2020;6(1):81\u20138.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"10","key":"1962_CR30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s00392-021-01854-7","volume":"110","author":"T Tobias Koch","year":"2021","unstructured":"Tobias Koch T, Lenz M, Joner, et al. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus: results of the Intracoronary Stenting and Angiographic results: test efficacy of Sirolimus- and probucol- and zotarolimus-eluting stents (ISAR-TEST 5) trial. Clin Res Cardiol. 2021;110(10):1586\u201398.","journal-title":"Clin Res Cardiol"},{"key":"1962_CR31","first-page":"250518","volume":"2011","author":"A Tufano","year":"2011","unstructured":"Tufano A, Cimino E, Minno MNDD, Ieran\u00f2 P, Marrone E, Strazzullo A, Di Minno G, Cerbone AM. Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs. Int J Vasc Med. 2011;2011:250518.","journal-title":"Int J Vasc Med"},{"issue":"4","key":"1962_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2174\/157016112800812818","volume":"10","author":"L Erik","year":"2012","unstructured":"Erik L, Grove S. Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol. 2012;10(4):494\u2013505.","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"1962_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13300-022-01350-9","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Xie X, Zu Q, et al. Treatment of the New era: long-term Ticagrelor Monotherapy for the treatment of patients with type 2 diabetes Mellitus following percutaneous coronary intervention: a Meta-analysis. Diabetes Ther. 2023;14(1):47\u201361.","journal-title":"Diabetes Ther"},{"issue":"2","key":"1962_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000368073","volume":"130","author":"YN Lin Zhu","year":"2015","unstructured":"Lin Zhu YN, Lv L. Stent thrombosis with biodegradable polymer drug-eluting stents versus durable polymer sirolimus-eluting stents: an update meta-analysis. Cardiology. 2015;130(2):96\u2013105.","journal-title":"Cardiology"},{"issue":"6","key":"1962_CR35","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.1002\/ccd.25416","volume":"83","author":"A Lupi","year":"2014","unstructured":"Lupi A, Secco GG, Rognoni A, et al. Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update. Catheter Cardiovasc Interv. 2014;83(6):E193\u2013206.","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01962-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01962-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01962-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T23:19:23Z","timestamp":1700349563000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01962-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1962"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01962-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not applicable for this systematic review and meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"228"}}